Related Experiment Video

Updated: Mar 3, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K

Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors

Ping Duan1, Lili Fan2, Quansheng Gao3

  • 1Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China.

Current Drug Targets
|April 27, 2017
PubMed

Insights

Targeting angiogenesis pathways with anti-angiogenic therapy shows promise for ovarian cancer, potentially improving survival when combined with chemotherapy, especially for high-risk patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeting ligand-receptor interactions in angiogenic pathways can enhance chemotherapy efficacy and reduce side effects.
  • Anti-angiogenic therapy has rapidly advanced as a targeted strategy in cancer treatment over the last decade.
  • It is a highly promising targeted therapy for ovarian cancer.

Purpose of the Study:

  • To summarize major anti-angiogenic agents used in ovarian cancer.
  • To review molecular mechanisms and clinical trial results of existing agents.
  • To discuss the development of new agents, limitations, and side effects.

Main Methods:

  • Review of published data on anti-angiogenic agents for ovarian cancer.
  • Analysis of molecular mechanisms of action.
  • Evaluation of clinical trial outcomes and ongoing developments.

Main Results:

  • Bevacizumab addition to chemotherapy may improve overall survival (OS) in ovarian cancer patients, particularly those with poor prognosis.
  • Several anti-angiogenic agents are established or under investigation for ovarian cancer treatment.
  • Understanding of molecular targets and clinical efficacy is expanding.

Conclusions:

  • Anti-angiogenic therapy, including bevacizumab, is a key strategy in ovarian cancer treatment.
  • Further research is ongoing for novel agents and improved therapeutic approaches.
  • Careful consideration of limitations and side effects is crucial for effective clinical application.
Keywords:
Ovarian cancerangiogenesisanti-angiogenic agentscancer therapyinhibitormolecular targeting

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K